Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 1:109:9.10.1-9.10.8.
doi: 10.1002/0471142735.im0910s109.

Use of proteasome inhibitors

Sondra L Downey  1 , Bogdan I Florea  2 , Herman S Overkleeft  2 , Alexei F Kisselev  1
Affiliations

Use of proteasome inhibitors

Sondra L Downey et al. Curr Protoc Immunol. .

Abstract

Proteasome inhibitors are indispensable research tools in immunology and cell biology. With numerous proteasome inhibitors available commercially, choosing the appropriate compound for a biological experiment may be challenging, especially for a novice. This unit provides an overview of the proteasome inhibitors commonly used in research. It discusses how to select an appropriate highly specific inhibitor, its concentration, and length of exposure for mammalian cell culture experiments. In addition, assays that can be used to confirm proteasome inhibition are discussed.

Keywords: boronates; peptide aldehydes; peptide epoxyketones; proteosome inhibitors.

PubMed Disclaimer

References

Literature Cited

    1. Adams, J. , Behnke, M. , Chen, S. , Cruickshank, A.A. , Dick, L.R. , Grenier, L. , Klunder, J.M. , Ma, Y.T. , Plamondon, L. , and Stein, R.L. 1998. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8:333-338.
    1. Anchoori, R.K. , Karanam, B. , Peng, S. , Wang, J.W. , Jiang, R. , Tanno, T. , Orlowski, R.Z. , Matsui, W. , Zhao, M. , Rudek, M.A. , Hung, C.F. , Chen, X. , Walters, K.J. , and Roden, R.B. 2013. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Can. Cell 24:791-805.
    1. Arastu-Kapur, S. , Anderl, J.L. , Kraus, M. , Parlati, F. , Shenk, K.D. , Lee, S.J. , Muchamuel, T. , Bennett, M.K. , Driessen, C. , Ball, A.J. , and Kirk, C.J. 2011. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events. Clin. Cancer Res. 17:2734-2743.
    1. Arendt, C.S. and Hochstrasser, M. 1997. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc. Natl. Acad. Sci. 94:7156-7161.
    1. Bachovchin, D.A. , Koblan, L.W. , Wu, W. , Liu, Y. , Li, Y. , Zhao, P. , Woznica, I. , Shu, Y. , Lai, J.H. , Poplawski, S.E. , Kiritsy, C.P. , Healey, S.E. , DiMare, M. , Sanford, D.G. , Munford, R.S. , Bachovchin, W.W. , and Golub, T.R. 2014. A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat. Chem. Biol. 10:656-663.

LinkOut - more resources